Table 4 Factors in relation to 90-day poor prognosis after acute intracerebral hemorrhage

Number

61

63

Age (years)

61.7 ± 11.8

61.3 ± 12.7

0.826

Gender (male/female)

29/32

40/23

0.074

Body mass index (kg/m²)

25.8 ± 3.4

25.6 ± 3.5

0.828

Hypertension

37 (60.7%)

37 (58.7%)

0.827

Diabetes mellitus

12 (19.7%)

16 (25.4%)

0.446

Hyperlipidemia

19 (31.1%)

19 (30.2%)

0.905

Coronary heart disease

6 (9.8%)

3 (4.8%)

0.319

Cigarette smoking

22 (36.1%)

22 (34.9%)

0.894

Alcohol drinking

23 (37.7%)

19 (30.2%)

0.375

Pretreatment of statins

17 (27.9%)

14 (22.2%)

0.468

Pretreatment of anticoagulation drugs

3 (4.9%)

2 (3.2%)

0.677

Pretreatment of antiplatelet drugs

7 (11.5%)

9 (14.3%)

0.641

Pretreatment of antihypertensive drugs

35 (57.4%)

32(50.8%)

0.462

Pretreatment of hypoglycemic drugs or insulin

11 (18.0%)

10 (15.9%)

0.749

Admission time (h)

9.4 (7.0-12.6)

9.1 (5.3–14.9)

0.910

Blood-collection time (h)

11.1 (8.5–14.8)

10.8 (6.7–16.6)

0.787

Systolic arterial pressure (mmHg)

146.5 ± 23.6

146.3 ± 22.7

0.967

Diastolic arterial pressure (mmHg)

88.0 ± 11.1

87.5 ± 10.8

0.784

Hemorrhage locations (lobar / deep)

17/44

15/48

0.606

Extension of hematoma into intraventricular cavity

19 (31.1%)

13 (20.6%)

0.181

Extension of hematoma into subarachnoidal space

8 (13.1%)

3 (4.8%)

0.102

NIHSS scores

10 (8–13)

6 (3–8)

< 0.001

Hematoma volume (ml)

23 (16–29)

11 (7–15)

< 0.001

Blood leucocyte count (×10⁹/l)

8.8 (6.8–11.3)

7.6 (6.3–9.5)

0.057

Blood glucose levels (mmol/l)

12.8 (9.6–17.2)

10.7 (9.2–12.4)

0.017

Serum MANF levels > 62.0 ng/ml

30 (49.2%)

5 (7.9%)

< 0.001